

Wearable Injectors Market by Type(On-body, Off-body), Technology (Spring, Motor Drive, Expanding Battery, Rotary Pump), Indications (Diabetes, Immuno-Oncology, Cardiovascular, Chronic Pain), End Users (Hospital & Clinic, Homecare) - Global Forecast to 2029

<https://marketpublishers.com/r/W7B8F9B8D23EN.html>

Date: February 2024

Pages: 237

Price: US\$ 4,950.00 (Single User License)

ID: W7B8F9B8D23EN

Abstracts

The global wearable injectors market is projected to reach USD 15.1 billion by 2029 from USD 8.4 billion in 2023, at a CAGR of 10.3% during the forecast period. Precise, user-friendly design, efficient delivery of large molecules, favorable reimbursements, numerous applications in drug delivery, the seamless subcutaneous flow of drugs, rise in the adoption of chronic diseases, and increased adoption of convenient drug delivery devices. The increased cost of wearable injectors and the high use of injection pens are challenges to growth in wearable injectors.

'On body wearable injectors segment accounted for the largest share and is expected to grow at the highest rate during the forecast period.'

On-body injectors, often equipped with the wisdom of smart features, offer a window into medication administration and adherence. Missed doses become a distant memory, usage patterns focus, and timely reminders keep the treatment waltz in rhythm, leading to improved health and fewer complications. Miniaturization promises a lighter, more discreet, while advancements in data security and accessibility will break down the barriers to entry. As manufacturers focus on affordability and diverse needs, on-body injectors have the potential to democratize healthcare, empowering millions to take control of their health with newfound confidence and independence.

'The rotary pump segment accounted for the highest growth during the forecast period.'

Unlike spring-based or motor-driven systems, rotary pumps deliver unwavering accuracy in medication dosage. Their fluid mechanics ensure consistent flow, minimizing the risk of errors and maximizing therapeutic effectiveness, particularly for medications requiring precise micro-doses. will drive the growth of the wearable injectors market. Rotary pumps achieve this magic with their smooth, low-pressure delivery, reducing pain and discomfort for patients, especially those with needle anxieties. Plus, their compact design translates to discreet and convenient use, seamlessly integrating into daily routines.

'Immuno oncology segment accounted for the second largest share of the market.'

Wearable injectors, with their user-friendly designs and intuitive interfaces, become an extension of the patient's therapeutic rhythm, reducing the dissonance of missed doses and ensuring sustained efficacy. This harmonization potentially amplifies treatment outcomes, particularly in immuno-oncology where precise administration is crucial. However, the score of healing can be laced with discomfort, a disruptive counterpoint for patients already battling their disease. Here, wearable injectors offer a gentle counter-melody. Their low-pressure delivery minimizes the cacophonous notes of injection anxiety, allowing patients to focus on the therapeutic crescendo within. This newfound autonomy, the ability to self-administer at their own tempo, liberates patients from the clinical constraints, transforming them into soloists in their own health journey.

"Hospitals and clinics are the end-user segment held the largest market share in the wearable injectors market.'

Wearable injectors are quietly claiming center stage, emerging as discreet allies in chronic disease management. These compact companions, adhering directly to the body, orchestrate medication delivery with precision, often minimizing the overall number of injections and granting patients an unprecedented level of control over their treatment. The allure of these miniature maestros lies in their ability to transcend the confines of hospital walls. Imagine ditching the sterile atmosphere and lengthy waits for home-based medication administration. Wearable injectors liberate patients from the shackles of institutional routines, reducing unnecessary clinic visits and the associated risk of hospital-acquired infections. This shift not only empowers individuals but also aligns with the digital health revolution, paving the way for seamless connectivity and remote monitoring of chronic conditions.

“North America to Witness Significant Growth From 2023 to 2029.”

Wearable injectors market has been segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America and Middle East and Africa and GCC. In 2022, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) during the forecast period. However, the North American market held the largest market share of the global market. North America stands as the frontrunner in the wearable injectors market, commanding the largest market share throughout the forecast period. North America boasts a well-developed healthcare infrastructure, fertile ground for nurturing research and development of cutting-edge technologies. Leading manufacturers find a welcoming stage here, their expertise fueling a thriving ecosystem of collaboration with universities, research labs, and other industry players. This collaborative spirit results in a constant crescendo of innovation, propelling the wearable injector market forward.

Breakdown of supply-side primary interviews: %li%By Company Type: Tier 1 – 35%, Tier 2 – 50%, and Tier 3 – 15% %li%By Designation: C-level – 35%, Director-level – 40%, and Others – 25% %li%By Region: North America - 30%, Europe – 25%, APAC – 20%, Latin America – 15%, Middle East & Africa – 7% GCC- 3%

Some of the prominent players in the wearable injectors market are Amgen Inc. (US), Medtronic PLC (Europe), Insulet Corporation (US), Tandem Diabetes Care, Inc. (US), United Therapeutics Corporation (US), Abbvie Inc. (US), Gerresheimer AG (Germany), Becton Dickinson and Company (US), West Pharmaceutical Services Inc. (US), Ypsomed AG (Switzerland), Enable Injections (US), Subcutject APS (Denmark), Cequr Simplicity (Switzerland), Mannkind Corporation (US), Sonceboz (Switzerland), CC Bio (Japan), Elcam Drug Delivery Devices (Israel), Stevanato Group (Italy), Debiotech SA (Switzerland), Bexson Biomedical (US), Nemera (France), LTS Lohmann Therapie Systeme AG (Germany), Kymanox Corporation (US), Novo Engineering (US), and Eoflow (South Korea).

Research Coverage

This report studies the wearable injectors market based on type, technology, indication, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual

growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

Analysis of key drivers (increasing prevalence of diabetes, technological advancements in wearable injectors devices, advent of artificial intelligence in wearable injectors, favorable reimbursements scenario in major markets, low-complexity, easy-to-use wearable injection platform), restraints (high cost of wearable injectors, oral insulin as an alternative drug delivery method), opportunities (increasing research and development activities and strategic partnerships and increased adoption of on-body wearable injectors), and challenges (needlestick injuries and misuse of injection pens) influencing the growth of wearable injectors market.

Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in wearable injectors market.

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of respiratory diagnostics across regions.

Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in wearable injectors market.

Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the wearable injectors market.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.3 INCLUSIONS & EXCLUSIONS

1.4 MARKET SCOPE

1.4.1 MARKETS COVERED

1.4.2 REGIONS COVERED

1.4.3 YEARS CONSIDERED

1.4.4 CURRENCY CONSIDERED

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD

1.5 STAKEHOLDERS

1.6 SUMMARY OF CHANGES

1.6.1 RECESSION IMPACT: WEARABLE INJECTORS MARKET

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 1 RESEARCH DESIGN

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

FIGURE 2 PRIMARY SOURCES

2.1.2.1 Key data from primary sources

2.1.2.2 Key industry insights

2.1.2.3 Breakdown of primary interviews

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION

FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS

2.2 MARKET SIZE ESTIMATION

FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS

FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: AMGEN INC.

FIGURE 8 SUPPLY-SIDE ANALYSIS OF TOP COMPANIES: WEARABLE

INJECTORS MARKET (2022)

FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, 2023–2029

FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

FIGURE 11 TOP-DOWN APPROACH

2.3 DATA TRIANGULATION

FIGURE 12 MARKET DATA TRIANGULATION

2.4 MARKET SHARE ESTIMATION

2.5 STUDY ASSUMPTIONS

2.6 RESEARCH LIMITATIONS

2.6.1 METHODOLOGY-RELATED LIMITATIONS

2.6.2 SCOPE-RELATED LIMITATIONS

2.7 RISK ASSESSMENT

TABLE 2 RISK ASSESSMENT: WEARABLE INJECTORS MARKET

2.8 IMPACT OF ECONOMIC RECESSION ON WEARABLE INJECTORS MARKET

3 EXECUTIVE SUMMARY

FIGURE 13 WEARABLE INJECTORS MARKET, BY TYPE, 2023 VS. 2029 (USD MILLION)

FIGURE 14 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2023 VS. 2029 (USD MILLION)

FIGURE 15 WEARABLE INJECTORS MARKET, BY INDICATION, 2023 VS. 2029 (USD MILLION)

FIGURE 16 WEARABLE INJECTORS MARKET, BY END USER, 2023 VS. 2029 (USD MILLION)

FIGURE 17 REGIONAL SNAPSHOT OF WEARABLE INJECTORS MARKET

4 PREMIUM INSIGHTS

4.1 WEARABLE INJECTORS MARKET OVERVIEW

FIGURE 18 INCREASING PREVALENCE OF CHRONIC DISEASES AND RISING HEALTHCARE EXPENDITURE TO DRIVE MARKET

4.2 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER & REGION, 2022

FIGURE 19 CHINA AND HOSPITALS AND CLINICS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022

4.3 GEOGRAPHIC GROWTH OPPORTUNITIES: WEARABLE INJECTORS MARKET

FIGURE 20 US TO REGISTER HIGHEST MARKET GROWTH RATE DURING

FORECAST PERIOD

4.4 WEARABLE INJECTORS MARKET: DEVELOPED VS. EMERGING ECONOMIES

FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES: WEARABLE INJECTORS MARKET

5.2.1 DRIVERS

5.2.1.1 Increasing prevalence of diabetes among geriatric population

TABLE 3 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS (20–79 YEARS), 2021 VS. 2045

5.2.1.2 Technological advancements in wearable injectors

5.2.1.3 Use of artificial intelligence in diabetes care devices

5.2.1.4 Favorable reimbursement scenario

5.2.1.5 Development of low-complexity and easy-to-use wearable injectors

5.2.2 RESTRAINTS

5.2.2.1 High cost of wearable injectors and lack of reimbursement plans in emerging economies

5.2.2.2 Increased focus on alternative drug delivery methods

5.2.3 OPPORTUNITIES

5.2.3.1 Increased number of R&D activities and strategic partnerships

5.2.3.2 Growing adoption of on-body wearable injectors

5.2.4 CHALLENGES

5.2.4.1 Lack of training and education for using new delivery devices

5.3 INDUSTRY TRENDS

5.3.1 INCREASING ADOPTION OF WEARABLE DRUG DELIVERY SYSTEMS

5.3.2 RISING NUMBER OF COLLABORATIONS AMONG STAKEHOLDERS

TABLE 4 RECENT COLLABORATIONS IN WEARABLE INJECTORS MARKET

5.3.3 INTEGRATION OF LIQUID SILICONE RUBBER TECHNOLOGY IN WEARABLE HEALTH MONITORING AND DRUG DELIVERY DEVICES

5.4 TECHNOLOGY ANALYSIS

5.5 SUPPLY CHAIN ANALYSIS

FIGURE 23 SUPPLY CHAIN ANALYSIS: WEARABLE INJECTORS MARKET

5.6 VALUE CHAIN ANALYSIS

FIGURE 24 VALUE CHAIN ANALYSIS: WEARABLE INJECTORS MARKET

5.7 ECOSYSTEM MARKET/MAP

FIGURE 25 ECOSYSTEM MARKET/MAP: WEARABLE INJECTORS MARKET

5.8 TRADE ANALYSIS

TABLE 5 IMPORT AND EXPORT DATA FOR WEARABLE INJECTORS, BY COUNTRY

5.9 PORTER'S FIVE FORCES ANALYSIS

TABLE 6 PORTER'S FIVE FORCES ANALYSIS: WEARABLE INJECTORS MARKET

5.9.1 INTENSITY OF COMPETITIVE RIVALRY

5.9.2 BARGAINING POWER OF SUPPLIERS

5.9.3 BARGAINING POWER OF BUYERS

5.9.4 THREAT OF SUBSTITUTES

5.9.5 THREAT OF NEW ENTRANTS

5.10 TARIFF & REGULATORY LANDSCAPE

5.10.1 REGULATORY ANALYSIS

5.10.1.1 North America

5.10.1.1.1 US

5.10.1.1.2 Canada

5.10.1.2 Europe

5.10.1.3 Asia Pacific

5.10.1.3.1 China

5.10.1.3.2 Japan

5.10.1.3.3 India

5.10.1.4 Latin America

5.10.1.4.1 Brazil

5.10.1.4.2 Mexico

5.10.1.5 Middle East

5.10.1.6 Africa

5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 11 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.11 PATENT ANALYSIS

5.11.1 PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS

FIGURE 26 PATENT PUBLICATION TRENDS (JANUARY 2018–MAY 2023)

5.11.2 TOP APPLICANTS (COMPANIES) FOR WEARABLE INJECTOR PATENTS

FIGURE 27 TOP APPLICANT COMPANIES FOR WEARABLE INJECTOR PATENTS, 2018–2023

5.11.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR WEARABLE INJECTOR PATENTS

FIGURE 28 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR WEARABLE INJECTOR PATENTS, 2018–2023

5.12 PRICING ANALYSIS

5.12.1 AVERAGE SELLING PRICE OF WEARABLE INJECTORS, BY KEY PLAYER

TABLE 12 AVERAGE SELLING PRICE OF WEARABLE INJECTORS, BY KEY PLAYERS, 2022

5.13 KEY CONFERENCES & EVENTS, 2023–2024

TABLE 13 DETAILED LIST OF KEY CONFERENCES & EVENTS IN WEARABLE INJECTORS MARKET, 2023–2024

5.14 KEY STAKEHOLDERS & BUYING CRITERIA

5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE DISEASES

TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE DISEASES (%)

5.14.2 BUYING CRITERIA

FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE DISEASES

TABLE 15 KEY BUYING CRITERIA FOR TOP THREE DISEASES

5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

5.16 UNMET NEEDS

5.17 ADJACENT MARKET ANALYSIS

FIGURE 31 ADJACENT MARKETS TO WEARABLE INJECTORS MARKET

6 WEARABLE INJECTORS MARKET, BY TYPE

6.1 INTRODUCTION

TABLE 16 WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

6.2 ON-BODY WEARABLE INJECTORS

6.2.1 ON-BODY WEARABLE INJECTORS TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD

TABLE 17 WEARABLE INJECTORS MARKET FOR ON-BODY WEARABLE

INJECTORS, BY COUNTRY, 2021–2029 (USD MILLION)

6.3 OFF-BODY WEARABLE INJECTORS

6.3.1 EASY AND CONTINUOUS DRUG DELIVERY AT REGULAR INTERVALS TO DRIVE MARKET

TABLE 18 WEARABLE INJECTORS MARKET FOR OFF-BODY WEARABLE INJECTORS, BY COUNTRY, 2021–2029 (USD MILLION)

6.4 DEVICE-ONLY WEARABLE INJECTORS

6.4.1 EASE OF ADMINISTRATION TO SUPPORT MARKET GROWTH

TABLE 19 WEARABLE INJECTORS MARKET FOR DEVICE-ONLY WEARABLE INJECTORS, BY COUNTRY, 2021–2029 (USD MILLION)

7 WEARABLE INJECTORS MARKET, BY TECHNOLOGY

7.1 INTRODUCTION

TABLE 20 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

7.2 SPRING-BASED TECHNOLOGY

7.2.1 MINIMAL DISCOMFORT AND ANXIETY FOR PATIENTS WITH NEEDLE PHOBIA TO PROPEL MARKET

TABLE 21 WEARABLE INJECTORS MARKET FOR SPRING-BASED TECHNOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)

7.3 MOTOR-DRIVEN TECHNOLOGY

7.3.1 TECHNOLOGICAL ADVANCEMENTS AND IMPROVED SAFETY TO AID MARKET GROWTH

TABLE 22 WEARABLE INJECTORS MARKET FOR MOTOR-DRIVEN TECHNOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)

7.4 ROTARY PUMP TECHNOLOGY

7.4.1 HIGHER PRECISION AND BETTER CONTROL OVER VISCOUS MEDICINES TO SUPPORT MARKET GROWTH

TABLE 23 WEARABLE INJECTORS MARKET FOR ROTARY PUMP TECHNOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)

7.5 EXPANDING BATTERY TECHNOLOGY

7.5.1 REDUCED PRODUCTION COST AND EASE OF USAGE TO DRIVE MARKET

TABLE 24 WEARABLE INJECTORS MARKET FOR EXPANDING BATTERY TECHNOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)

7.6 OTHER TECHNOLOGIES

TABLE 25 WEARABLE INJECTORS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)

8 WEARABLE INJECTORS MARKET, BY INDICATION

8.1 INTRODUCTION

TABLE 26 WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

8.2 DIABETES

8.2.1 HIGH PREVALENCE OF DIABETES TO DRIVE MARKET

TABLE 27 INSULIN DEVICES AVAILABLE FOR DIABETIC PATIENTS

TABLE 28 WEARABLE INJECTORS MARKET FOR DIABETES, BY COUNTRY, 2021–2029 (USD MILLION)

8.3 IMMUNO-ONCOLOGY

8.3.1 INCREASING NUMBER OF CANCER CASES TO BOOST MARKET GROWTH

TABLE 29 WEARABLE INJECTORS MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2021–2029 (USD MILLION)

8.4 CARDIOVASCULAR DISEASES

8.4.1 RISING CASES OF HEART FAILURE AMONG ADULTS TO PROPEL MARKET GROWTH

TABLE 30 WEARABLE INJECTORS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)

8.5 CHRONIC PAINS

8.5.1 INCREASING RESEARCH IN PAIN MANAGEMENT TO SUPPORT MARKET GROWTH

TABLE 31 WEARABLE INJECTORS MARKET FOR CHRONIC PAINS, BY COUNTRY, 2021–2029 (USD MILLION)

8.6 OTHER DISEASES

TABLE 32 WEARABLE INJECTORS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)

9 WEARABLE INJECTORS MARKET, BY END USER

9.1 INTRODUCTION

TABLE 33 WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

9.2 HOSPITALS AND CLINICS

9.2.1 HOSPITALS AND CLINICS TO COMMAND LARGEST END-USER SEGMENT OF END USER DURING STUDY PERIOD

TABLE 34 WEARABLE INJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)

9.3 HOME CARE SETTINGS

9.3.1 RISING PREFERENCE FOR SELF-ADMINISTRATION OF MEDICINE TO DRIVE MARKET

TABLE 35 WEARABLE INJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)

9.4 OTHER END USERS

TABLE 36 WEARABLE INJECTORS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)

10 WEARABLE INJECTORS MARKET, BY REGION

10.1 INTRODUCTION

FIGURE 32 WEARABLE INJECTORS MARKET: REGIONAL SNAPSHOT

TABLE 37 WEARABLE INJECTORS MARKET, BY REGION, 2021–2029 (USD MILLION)

10.2 NORTH AMERICA

FIGURE 33 NORTH AMERICA: WEARABLE INJECTORS MARKET SNAPSHOT

TABLE 38 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)

TABLE 39 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 40 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 41 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 42 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.2.1 NORTH AMERICA: RECESSION IMPACT

10.2.2 US

10.2.2.1 Favorable reimbursement scenario and high prevalence of chronic diseases to drive market

TABLE 43 US: KEY MACROINDICATORS

TABLE 44 US: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 45 US: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 46 US: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 47 US: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.2.3 CANADA

10.2.3.1 Growing biologics market to propel market growth

TABLE 48 CANADA: KEY MACROINDICATORS

TABLE 49 CANADA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 50 CANADA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 51 CANADA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 52 CANADA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.3 EUROPE

TABLE 53 EUROPE: WEARABLE INJECTORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)

TABLE 54 EUROPE: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 55 EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 56 EUROPE: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 57 EUROPE: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.3.1 EUROPE: RECESSION IMPACT

10.3.2 GERMANY

10.3.2.1 Favorable government policies for drug development and approval to aid market growth

TABLE 58 GERMANY: KEY MACROINDICATORS

TABLE 59 GERMANY: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 60 GERMANY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 61 GERMANY: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 62 GERMANY: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.3.3 FRANCE

10.3.3.1 Increased prevalence of diabetes and favorable insurance coverage by SHI to drive market

TABLE 63 FRANCE: KEY MACROINDICATORS

TABLE 64 FRANCE: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 65 FRANCE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 66 FRANCE: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 67 FRANCE: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.3.4 UK

10.3.4.1 Rising focus on development and promotion of biosimilars and biologics to propel market growth

TABLE 68 UK: KEY MACROINDICATORS

TABLE 69 UK: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 70 UK: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 71 UK: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 72 UK: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.3.5 ITALY

10.3.5.1 Rising prevalence of diabetes to support market growth

TABLE 73 ITALY: MACROECONOMIC INDICATORS

TABLE 74 ITALY: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 75 ITALY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 76 ITALY: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 77 ITALY: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.3.6 SPAIN

10.3.6.1 Increased preference for less painful drug delivery systems among geriatric population to drive market

TABLE 78 SPAIN: MACROECONOMIC INDICATORS

TABLE 79 SPAIN: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 80 SPAIN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 81 SPAIN: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029
(USD MILLION)

TABLE 82 SPAIN: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029
(USD MILLION)

10.3.7 REST OF EUROPE

TABLE 83 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY TYPE,
2021–2029 (USD MILLION)

TABLE 84 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY
TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 85 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY INDICATION,
2021–2029 (USD MILLION)

TABLE 86 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY END USER,
2021–2029 (USD MILLION)

10.4 ASIA PACIFIC

FIGURE 34 ASIA PACIFIC: WEARABLE INJECTORS MARKET SNAPSHOT

TABLE 87 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY COUNTRY,
2021–2029 (USD MILLION)

TABLE 88 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029
(USD MILLION)

TABLE 89 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2021–2029 (USD MILLION)

TABLE 90 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY INDICATION,
2021–2029 (USD MILLION)

TABLE 91 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER,
2021–2029 (USD MILLION)

10.4.1 ASIA PACIFIC: RECESSION IMPACT

10.4.2 JAPAN

10.4.2.1 Increasing number of patients suffering from diabetes, CVD, and chronic conditions to drive market

TABLE 92 JAPAN: MACROECONOMIC INDICATORS

TABLE 93 JAPAN: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD
MILLION)

TABLE 94 JAPAN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY,
2021–2029 (USD MILLION)

TABLE 95 JAPAN: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029
(USD MILLION)

TABLE 96 JAPAN: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029
(USD MILLION)

10.4.3 CHINA

10.4.3.1 Favorable government initiatives and improved access to advanced healthcare to drive market

TABLE 97 CHINA: MACROECONOMIC INDICATORS

TABLE 98 CHINA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 99 CHINA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 100 CHINA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 101 CHINA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.4.4 INDIA

10.4.4.1 Growing burden of diabetes and increasing need to reduce healthcare costs to propel market

TABLE 102 INDIA: MACROECONOMIC INDICATORS

TABLE 103 INDIA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 104 INDIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 105 INDIA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 106 INDIA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.4.5 AUSTRALIA

10.4.5.1 Favorable government initiatives for diabetes treatment to drive market

TABLE 107 AUSTRALIA: MACROECONOMIC INDICATORS

TABLE 108 AUSTRALIA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 109 AUSTRALIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 110 AUSTRALIA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 111 AUSTRALIA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.4.6 SOUTH KOREA

10.4.6.1 Increased number of government initiatives for diabetes management to drive market

TABLE 112 SOUTH KOREA: KEY MACROINDICATORS

TABLE 113 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY TYPE,

2021–2029 (USD MILLION)

TABLE 114 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 115 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 116 SOUTH KOREA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.4.7 REST OF ASIA PACIFIC

TABLE 117 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 118 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 119 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 120 REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.5 LATIN AMERICA

TABLE 121 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)

TABLE 122 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 123 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 124 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 125 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.5.1 LATIN AMERICA: RECESSION IMPACT

10.5.2 BRAZIL

10.5.2.1 Increasing number of government initiatives for improving healthcare sector to boost market

TABLE 126 BRAZIL: MACROECONOMIC INDICATORS

TABLE 127 BRAZIL: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 128 BRAZIL: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 129 BRAZIL: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 130 BRAZIL: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029

(USD MILLION)

10.5.3 MEXICO

10.5.3.1 Increasing prevalence of diabetes and obesity-related diseases to boost market growth

TABLE 131 MEXICO: KEY MACROINDICATORS

TABLE 132 MEXICO: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 133 MEXICO: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 134 MEXICO: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 135 MEXICO: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.5.4 REST OF LATIN AMERICA

TABLE 136 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 137 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 138 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 139 REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.6 MIDDLE EAST & AFRICA

TABLE 140 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY REGION, 2021–2029 (USD MILLION)

TABLE 141 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 142 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 143 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 144 MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT

10.6.2 GCC COUNTRIES

10.6.2.1 Growing incidence of chronic diseases to propel market

TABLE 145 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 146 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY

TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 147 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 148 GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

10.6.3 REST OF MIDDLE EAST & AFRICA

TABLE 149 REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021–2029 (USD MILLION)

TABLE 150 REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)

TABLE 151 REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021–2029 (USD MILLION)

TABLE 152 REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2021–2029 (USD MILLION)

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION

11.2 KEY STRENGTHS/RIGHT TO WIN

FIGURE 35 STRATEGIES ADOPTED BY KEY PLAYERS IN WEARABLE INJECTORS MARKET, 2020–2024

11.3 REVENUE SHARE ANALYSIS

FIGURE 36 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2018–2022

11.4 MARKET SHARE ANALYSIS

FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022

11.5 MANUFACTURERS OF WEARABLE DEVICES

TABLE 153 LIST OF KEY MANUFACTURERS OF WEARABLE DEVICES

11.6 COMPANY EVALUATION MATRIX

11.6.1 STARS

11.6.2 EMERGING LEADERS

11.6.3 PERVASIVE PLAYERS

11.6.4 PARTICIPANTS

FIGURE 38 COMPANY EVALUATION MATRIX, 2022

11.6.5 COMPANY FOOTPRINT

TABLE 154 WEARABLE INJECTORS MARKET: OVERALL FOOTPRINT

TABLE 155 WEARABLE INJECTORS MARKET: PRODUCT FOOTPRINT

TABLE 156 WEARABLE INJECTORS MARKET: REGIONAL FOOTPRINT

11.7 START-UP/SME EVALUATION MATRIX

11.7.1 PROGRESSIVE COMPANIES

11.7.2 RESPONSIVE COMPANIES

11.7.3 DYNAMIC COMPANIES

11.7.4 STARTING BLOCKS

FIGURE 39 START-UP/SME EVALUATION MATRIX, 2022

11.7.5 COMPETITIVE BENCHMARKING

TABLE 157 DETAILED LIST OF KEY START-UPS/SMES

11.8 R&D EXPENDITURE

FIGURE 40 R&D EXPENDITURE OF KEY PLAYERS, 2021 VS. 2022

11.9 BRAND/PRODUCT COMPARISON

TABLE 158 BRAND/PRODUCT COMPARISON OF KEY PLAYERS

11.9.1 AMGEN INC.

11.9.2 MEDTRONIC

11.9.3 INSULET CORPORATION

11.9.4 TANDEM DIABETES CARE, INC.

11.9.5 UNITED THERAPEUTICS

11.9.6 ABBVIE INC.

11.9.7 GERRESHEIMER AG

11.10 INVESTMENT AND FUNDING SCENARIO

FIGURE 41 FUNDING IN WEARABLE INJECTORS MARKET SOARED IN 2022

11.10.1 FUNDING IN WEARABLE INJECTORS MARKET, BY INDICATION

TABLE 159 FUNDING IN WEARABLE INJECTORS MARKET, BY INDICATION

FIGURE 42 MOST VALUED WEARABLE INJECTORS FIRMS IN 2022 (USD BILLION)

11.11 COMPANY FINANCIAL METRICS

FIGURE 43 FINANCIAL METRICS OF KEY COMPANIES, 2022

11.12 COMPETITIVE SCENARIO

11.12.1 PRODUCT LAUNCHES & APPROVALS

TABLE 160 WEARABLE INJECTORS MARKET: PRODUCT LAUNCHES & APPROVALS, 2020–2024

11.12.2 DEALS

TABLE 161 WEARABLE INJECTORS MARKET: DEALS, 2020–2024

11.12.3 OTHER DEVELOPMENTS

TABLE 162 WEARABLE INJECTORS MARKET: OTHER DEVELOPMENTS, 2020–2024

12 COMPANY PROFILES

12.1 KEY PLAYERS

(Business overview, Products/Solutions/Services offered, Recent developments, Deals, MnM view, Key strengths/Right to win, Strategic choices, and Weaknesses and

Competitive threats)*

12.1.1 AMGEN INC.

TABLE 163 AMGEN INC.: COMPANY OVERVIEW

FIGURE 44 AMGEN INC.: COMPANY SNAPSHOT (2022)

TABLE 164 AMGEN INC.: DEALS, 2020–2024

TABLE 165 AMGEN INC.: OTHER DEVELOPMENTS, 2020–2024

12.1.2 MEDTRONIC

TABLE 166 MEDTRONIC: COMPANY OVERVIEW

FIGURE 45 MEDTRONIC: COMPANY SNAPSHOT (2022)

TABLE 167 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS, 2020–2024

TABLE 168 MEDTRONIC: DEALS, 2020–2024

12.1.3 INSULET CORPORATION

TABLE 169 INSULET CORPORATION: COMPANY OVERVIEW

FIGURE 46 INSULET CORPORATION: COMPANY SNAPSHOT (2022)

TABLE 170 INSULET CORPORATION: PRODUCT LAUNCHES & APPROVALS,
2020–2024

TABLE 171 INSULET CORPORATION: DEALS, 2020–2024

12.1.4 TANDEM DIABETES CARE, INC.

TABLE 172 TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW

FIGURE 47 TANDEM DIABETES CARE, INC.: COMPANY SNAPSHOT (2022)

TABLE 173 TANDEM DIABETES CARE, INC.: DEALS, 2020–2024

12.1.5 UNITED THERAPEUTICS CORPORATION

TABLE 174 UNITED THERAPEUTICS CORPORATION: COMPANY OVERVIEW

FIGURE 48 UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT
(2022)

TABLE 175 UNITED THERAPEUTICS CORPORATION: DEALS, 2020–2024

12.1.6 ABBVIE INC.

TABLE 176 ABBVIE INC.: COMPANY OVERVIEW

FIGURE 49 ABBVIE INC.: COMPANY SNAPSHOT (2022)

TABLE 177 ABBVIE INC.: PRODUCT LAUNCHES & APPROVALS, 2020–2024

12.1.7 GERRESHEIMER AG

TABLE 178 GERRESHEIMER AG: COMPANY OVERVIEW

FIGURE 50 GERRESHEIMER AG: COMPANY SNAPSHOT (2022)

TABLE 179 GERRESHEIMER AG: PRODUCT LAUNCHES & APPROVALS,
2020–2024

TABLE 180 GERRESHEIMER AG: DEALS, 2020–2024

12.1.8 BECTON, DICKINSON AND COMPANY

TABLE 181 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW

FIGURE 51 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)

TABLE 182 BECTON, DICKINSON AND COMPANY: DEALS, 2020–2024

TABLE 183 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS, 2020–2024

12.1.9 WEST PHARMACEUTICAL SERVICES, INC.

TABLE 184 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW

FIGURE 52 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2022)

12.1.10 YPSOMED HOLDING AG

TABLE 185 YPSOMED HOLDING AG: COMPANY OVERVIEW

FIGURE 53 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2022)

TABLE 186 YPSOMED HOLDING AG: PRODUCT LAUNCHES & APPROVALS, 2020–2024

TABLE 187 YPSOMED HOLDING AG: DEALS, 2020–2024

TABLE 188 YPSOMED HOLDING AG: OTHER DEVELOPMENTS, 2020–2024

12.1.11 ENABLE INJECTIONS

TABLE 189 ENABLE INJECTIONS: COMPANY OVERVIEW

TABLE 190 ENABLE INJECTIONS: PRODUCT LAUNCHES & APPROVALS, 2020–2024

TABLE 191 ENABLE INJECTIONS: DEALS, 2020–2024

TABLE 192 ENABLE INJECTIONS: OTHER DEVELOPMENTS, 2020–2024

12.1.12 SUBCUJECT APS

TABLE 193 SUBCUJECT APS: COMPANY OVERVIEW

12.1.13 CEQUR SIMPLICITY

TABLE 194 CEQUR SIMPLICITY: COMPANY OVERVIEW

TABLE 195 CEQUR SIMPLICITY: OTHER DEVELOPMENTS, 2020–2024

12.1.14 MANNKIND CORPORATION

TABLE 196 MANNKIND CORPORATION: COMPANY OVERVIEW

FIGURE 54 MANNKIND CORPORATION: COMPANY SNAPSHOT (2022)

TABLE 197 MANNKIND CORPORATION: DEALS, 2020–2024

TABLE 198 MANNKIND CORPORATION: OTHER DEVELOPMENTS, 2020–2024

12.1.15 SONCEBOZ

TABLE 199 SONCEBOZ: COMPANY OVERVIEW

12.1.16 CC BIO

TABLE 200 CC BIO: COMPANY OVERVIEW

TABLE 201 CC BIO: DEALS, 2020–2024

12.1.17 ELCAM DRUG DELIVERY DEVICES

TABLE 202 ELCAM DRUG DELIVERY DEVICES: COMPANY OVERVIEW

TABLE 203 ELCAM DRUG DELIVERY DEVICES: DEALS, 2020–2024

12.1.18 STEVANATO GROUP

TABLE 204 STEVANATO GROUP: COMPANY OVERVIEW**12.1.19 DEBIOTECH SA****TABLE 205 DEBIOTECH SA: COMPANY OVERVIEW****12.2 OTHER PLAYERS****12.2.1 BEXSON BIOMEDICAL****12.2.2 NEMERA****12.2.3 LTS LOHMANN THERAPIE-SYSTEME AG****12.2.4 KYMANOX CORPORATION****12.2.5 NOVO ENGINEERING****12.2.6 EOFLOW CO., LTD.**

*Details on Business overview, Products/Solutions/Services offered, Recent developments, Deals, MnM view, Key strengths/Right to win, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

13 APPENDIX**13.1 DISCUSSION GUIDE****13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL****13.3 CUSTOMIZATION OPTIONS****13.4 RELATED REPORTS****13.5 AUTHOR DETAILS**

I would like to order

Product name: Wearable Injectors Market by Type(On-body, Off-body), Technology (Spring, Motor Drive, Expanding Battery, Rotary Pump), Indications (Diabetes, Immuno- Oncology, Cardiovascular, Chronic Pain), End Users (Hospital & Clinic, Homecare) - Global Forecast to 2029

Product link: <https://marketpublishers.com/r/W7B8F9B8D23EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/W7B8F9B8D23EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970